Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Use of Mesalamine Pellet Formulation 1.5G QD to Maintain Remission From Mild to Moderate Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 May 2019
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors Bausch Health Companies; Salix Pharmaceuticals
- 13 Oct 2009 New trial record.